Zai Lab Announces First Quarter 2022 Financial Results and Corporate Updates

May 10, 2022

Read More

Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

May 05, 2022

Read More

Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study

Apr 28, 2022

Read More

Zai Lab Announces Engagement of KPMG LLP, a U.S. Auditor, as the Company’s Independent Registered Public Accounting Firm

Apr 21, 2022

Read More

Zai Lab to Announce First Quarter 2022 Financial Results on May 10, 2022

Apr 20, 2022

Read More

Zai Lab Plants a Tree for Every Employee on Earth Day 2022

Apr 19, 2022

Read More

Zai Lab to Present New Oncology Research at 2022 AACR Annual Meeting

Apr 06, 2022

Read More

Zai Lab Statement on SEC Listing Matter

Mar 28, 2022

Read More